 In a spat between Takeda Pharmaceutical Co Ltd NYSE: TAK and AbbVie Inc NYSE: ABBV for Lupron leuprorelin, a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with the prostate cancer drug. 